NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Support-HF product will support patients and clinicians in managing heart failure and curate data for medical research using Clinical AI
Oxford, UK; 8 August 2018: Sensyne Health Limited (the “Company”), formerly Drayson Health, a British clinical AI technology company, announces today it has signed an exclusive licence agreement for a fourth digital health software product as part of its five-year strategic research agreement with the University of Oxford and Oxford University Hospitals NHS Foundation Trust. Support-HF™ underpins a remote management service for patients with heart failure.
Following six years of R&D and a 30-month, 202-person randomised controlled trial (registered at ISCRTN 86212709), due to be submitted for publication in Q4 2018, the Company plans to develop a cloud-based scalable version of Support-HF to help support the management of heart failure at home.
The collaboration between Sensyne Health, the University of Oxford and the Oxford University Hospitals NHS Foundation Trust, established in July 2017, creates a pathway for the commercial development of digital health innovations invented and clinically validated by the University and the Trust. Support-HF is the latest product to be exclusively licensed to the Company by Oxford University Innovation, the technology transfer company of the University of Oxford, as part of this collaboration.
Heart failure affects 26 million people worldwide and is now considered a global epidemic1. In the UK, 900,000 patients are estimated to have the disease, with almost as many having damaged hearts who have not yet shown symptoms of heart failure2. Heart failure is currently the leading cause of hospital admissions for those aged 65 years and older with admissions expected to rise by 50% over the next 25 years3. The management of heart failure represents a significant cost burden to the NHS with 1-2% of the total annual budget estimated to be spent on the condition1.
Professor Kazem Rahimi, Honorary Consultant Cardiologist at the John Radcliffe Hospital, Oxford and Support-HF Chief Investigator at The George Institute for Global Health at the University of Oxford, commented: “This simple software enables heart failure patients to understand and monitor their condition and take control of their treatment in their own homes. An affordable, sustainable system, it has the potential to not only empower patients, but to strengthen the health system to bring specialist knowledge to non-specialists.”
LORD (PAUL) DRAYSON, CEO OF SENSYNE HEALTH, COMMENTED:
“Support HF has the potential to make significant improvements in the care of patients suffering from heart failure and is a further example of the pipeline of innovative digital health innovations coming out of research at Oxford. Sensyne Health will now develop the product so that it may be deployed more widely across the NHS and then internationally.”
DR JAMES GROVES, SENIOR LICENSING AND VENTURES MANAGER AT OXFORD UNIVERSITY INNOVATION, THE TECHNOLOGY TRANSFER COMPANY FOR THE UNIVERSITY OF OXFORD, COMMENTED:
“Support-HF is another example of cutting-edge digital health technology coming out of Oxford, created through the cross-disciplinary collaboration between doctors, engineers and software developers. We look forward to seeing this technology making a positive difference to the workload of doctors, the finances of the NHS and the health of patients suffering from heart failure.”
1. Cowie, Martin R, March 2017, The heart failure epidemic: a UK perspective. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435875/pdf/erp-4-R15.pdf
2. National Institute for Health and Care Excellence, Chronic heart failure in adults: management. Available at https://www.nice.org.uk/guidance/cg108/chapter/Introduction.
3. National Institute for Health and Care Excellence, Acute heart failure: diagnosis and management. Available at https://www.nice.org.uk/guidance/cg187/chapter/Introduction
For more information please contact:
Notes for editors:
The new agreement builds on an existing relationship with Chelsea and Westminster Hospital NHS Foundation Trust, formed in September 2017, when the parties announced a global first, piloting Sensyne Health’s wireless environmental sensors in intensive care units at Chelsea and Westminster Hospital.
ABOUT SENSYNE HEALTH
Sensyne Health is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts.
Sensyne Health, which recently changed its name from Drayson Health, is based in the Big Data Institute at the University of Oxford's Old Road Campus.
For more information, please visit: www.sensynehealth.com
Support-HF is a managed service using digital tools, intended to benefit both heart failure patients and their GP’s. It is designed to ensure patients are on an optimum treatment plan following NICE guidelines. Support-HF is comprised of a software application for use on a tablet by heart failure patients, together with a patient monitoring website accessible by healthcare professionals only. Heart failure patients are able to record data and access self-management tools at home via the app whilst health care professionals can track their patients’ health remotely and use the data to support clinical decision-making via the website. The patient’s app enables them to record automatically (via Bluetooth) daily vital signs data on blood pressure and weight alongside subjective symptom information that is entered manually. The application then shares this data with a specialist (cardiology) care team. The care team see alerts that are triggered when a patient’s data crosses pre-defined clinical risk thresholds. The care team also maintain a record for each patient on the system, recording data such as blood test results and medication. These data are either automatically pulled from cardiology lab systems or manually entered by the team depending on the Trust’s IT infrastructure. The care team can view, via the Support-HF system, information comprising data received from the patient, together with data from the patient’s health record and use this combined view of the patient to reach a judgement on the optimum intervention plan for the patient. This plan is then sent via email to the patient’s GP to implement.
Support-HF was developed by Prof. Kazem Rahimi and Prof. Lionel Tarassenko and their teams at the University of Oxford and Oxford University Hospitals NHS Foundation Trust with funding support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC).
INFORMATION GOVERNANCE AND DATA PROTECTION
Any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with the Caldicott Principles, UK data protection law and applicable regulatory guidance.
WHAT IS ‘CLINICAL AI’?
Clinical AI is a highly specialised field of AI which uses machine learning algorithms, including deep learning in tandem with human clinical expertise and big datasets with which to train the algorithms. Clinical AI is particularly concerned with the analysis of data acquired during routine clinical care of patients, in order to derive clinically-useful results such as to improve patient outcomes and to discover new insights about the use of pharmaceutical compounds to treat patients.
ABOUT OXFORD UNIVERSITY INNOVATION
Oxford University Innovation supports innovation activities across all University Divisions, managing technology transfer and consulting activities, and creating a world-leading innovation ecosystem, with Oxford University at its heart.
We provide access to technology from Oxford researchers through intellectual property licensing, spinout company formation and material sales, and to academic expertise through our Consulting Services team. The New Venture Support & Funding team supports investors or donors with an interest in early-stage ventures, and manages the Oxford Angels Network.
Our Startup Incubator supports members and ex-members of the University who wish to start or grow entrepreneur-driven ventures that are not University spinouts.
Oxford University Innovation is the highest university patent filer in the UK and is ranked 1st in the UK for university spinouts, having created over 170 new companies since 1988. In the 2016/17 financial year we completed more than 50 licenses and consulting agreements every month.
For updates on innovations from Oxford, follow Oxford University Innovation on LinkedIn and Twitter or subscribe at http://innovation.ox.ac.uk/about/contact-us/#enquiry
ABOUT THE UNIVERSITY OF OXFORD MEDICAL SCIENCES DIVISION
The University of Oxford Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK’s top-ranked medical school. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery. A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
This announcement does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever.
These materials are not an offer of securities for sale in the United States. The securities to which these materials relate have not been registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States.